Technical Analysis for KALV - KalVista Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 23.8 -2.34% -0.57
KALV closed down 2.34 percent on Friday, May 17, 2019, on 56 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Flat
See historical KALV trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.34%
20 DMA Support Bullish -2.34%
NR7 Range Contraction -2.34%
Inside Day Range Contraction -2.34%
20 DMA Support Bullish -1.77%
Outside Day Range Expansion -1.77%
Crossed Above 20 DMA Bullish -3.57%
Fell Below 20 DMA Bearish -0.29%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.41%

Older signals for KALV ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Medical Specialties Pharmaceutical Diseases Organ Systems Enzymes Diabetic Macular Edema Hereditary Angioedema Angioedema Protease Inhibitor
Is KALV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 34.92
52 Week Low 7.73
Average Volume 169,253
200-Day Moving Average 20.6126
50-Day Moving Average 25.9746
20-Day Moving Average 23.7235
10-Day Moving Average 23.806
Average True Range 1.5171
ADX 17.61
+DI 21.3153
-DI 16.5351
Chandelier Exit (Long, 3 ATRs ) 22.6987
Chandelier Exit (Short, 3 ATRs ) 26.0513
Upper Bollinger Band 26.1822
Lower Bollinger Band 21.2648
Percent B (%b) 0.52
BandWidth 20.72797
MACD Line -0.4189
MACD Signal Line -0.6275
MACD Histogram 0.2085
Fundamentals Value
Market Cap 231.16 Million
Num Shares 9.71 Million
EPS -3.07
Price-to-Earnings (P/E) Ratio -7.75
Price-to-Sales 202.03
Price-to-Book 4.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.53
Resistance 3 (R3) 25.60 25.10 25.24
Resistance 2 (R2) 25.10 24.66 25.06 25.15
Resistance 1 (R1) 24.45 24.38 24.20 24.38 25.05
Pivot Point 23.94 23.94 23.82 23.91 23.94
Support 1 (S1) 23.29 23.50 23.04 23.22 22.55
Support 2 (S2) 22.79 23.23 22.75 22.45
Support 3 (S3) 22.14 22.79 22.36
Support 4 (S4) 22.07